

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
Waivers under 18 U.S.C. §208(b)(1) and under 21 U.S.C. 355(n)(4)

John R. Teerlink, M.D.

Committees: Cardiovascular and Renal Drugs and the Drug Safety and Risk Management Advisory Committees

Meeting Dates: September 11, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of updated information on the risks and benefits of erythropoiesis-stimulating agents (ARANESP, Amgen, Inc., EPOGEN, Amgen, Inc. and PROCRT, Amgen, Inc.) when used in the treatment of anemia due to chronic renal failure. I am eligible to receive a waiver under 18 U.S.C. §208(b)(1) and 21 U.S.C. 355(n)(4).

Type of Interest	Nature	Magnitude
Blinded Endpoint Reviewer - Unrelated	Competing Firm	From \$10,001 to \$50,000 per year.
Consulting – Unrelated	Competing Firm	Less than \$10,001 per year.
Stock in a Health Sector Mutual Fund	Health Sector Mutual Fund	Valued at between \$50,001 and \$100,000.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/S/
Signature of SGE

08/02/2007
Date